Received Jun 2, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
she developed an pronounced local reaction redness and swelling of an area of approximately 3 by 3 in in diameter to this vaccine; she developed an pronounced local reaction redness and swelling of an area of approximately 3 by 3 in in diameter to this vaccine; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a 54-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 2 days after receiving Shingrix, the patient experienced injection site erythema (Verbatim: she developed an pronounced local reaction redness and swelling of an area of approximately 3 by 3 in in diameter to this vaccine) and injection site swelling (Verbatim: she developed an pronounced local reaction redness and swelling of an area of approximately 3 by 3 in in diameter to this vaccine). The patient was treated with ammonium chloride, diphenhydramine hydrochloride, sodium citrate (Diphenhydramine) and diphenhydramine hydrochloride (Benadryl). The outcome of the injection site erythema and injection site swelling were not reported. The reporter considered the injection site erythema and injection site swelling to be related to Shingrix. The company considered the injection site erythema and injection site swelling to be related to Shingrix. Additional Information: GSK Receipt Date: 28-MAY-2026 and 01-JUN-2026 The second dose is due on o6-JUL-26. Could you please provide guidance on administering the second dose, considering the localized reaction observed after the first dose. The reporter wanted to confirm was the safe to administer second dose. The patient exaggerated local reaction was observed, characterized by redness and swelling of an area approximately three inches in diameter at the injection site, occurring two to three days after administration of the first dose. The batch number was not provided upon follow up with the reporter.